Larotrectinib for treating advanced solid tumours with TRK fusions – final appraisal determination

DRAFT NICE guidance recommends Larotrectinib, for use within the CDF for NTRK fusion +ve solid tumours in adults and children if the disease is locally advanced or metastatic or surgery could cause severe health problems and they have no satisfactory treatment options.

Source:

National Institute for Health and Care Excellence